Literature DB >> 15210503

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection.

A Greenough1, J Alexander, S Burgess, J Bytham, P A J Chetcuti, J Hagan, W Lenney, S Melville, N J Shaw, J Boorman, S Coles, J Turner, F Pang.   

Abstract

BACKGROUND: In prematurely born infants with chronic lung disease (CLD), RSV hospitalisation is associated with increased health service utilisation and costs in the first two years after birth. AIMS: To determine whether RSV hospitalisation in the first two years was associated with chronic respiratory morbidity during the preschool years in prematurely born children who had had CLD.
METHODS: Retrospective review of readmissions, outpatient attendances, and community care in years 2-4 and, at age 5 years, assessment of the children's respiratory status and their health related quality of life. Comparison was made of the results of children who had had at least one hospitalisation in the first two years after birth for RSV infection (RSV group) to those of the rest of the cohort. Participants were 190 of an original cohort of 235 infants with CLD and a median gestational age 27 (range 22-33) weeks.
RESULTS: The 33 children in the RSV group, compared to the rest of the cohort, had a greater duration of hospital stay and more outpatient appointments. The RSV group had required more prescriptions for all treatments and respiratory medications, and more had used an inhaler. The cost of care of the RSV group was higher (median 2630 pounds sterling [4000 Euros, US4800 dollars], range 124-18,091 pounds sterling versus 1360 pounds sterling [2500 Euros, US3000 dollars], range 5-18 929 pounds sterling ) and their health related quality of life was lower.
CONCLUSION: In prematurely born children who had developed CLD, RSV hospitalisation in the first two years was associated with chronic respiratory morbidity and increased cost of care.

Entities:  

Mesh:

Year:  2004        PMID: 15210503      PMCID: PMC1720002          DOI: 10.1136/adc.2003.036129

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  7 in total

1.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2.

Authors:  G W Torrance; D H Feeny; W J Furlong; R D Barr; Y Zhang; Q Wang
Journal:  Med Care       Date:  1996-07       Impact factor: 2.983

2.  Respiratory status and allergy nine to 10 years after acute bronchiolitis.

Authors:  V Noble; M Murray; M S Webb; J Alexander; A S Swarbrick; A D Milner
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

3.  Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection.

Authors:  A Greenough; S Cox; J Alexander; W Lenney; F Turnbull; S Burgess; P A Chetcuti; N J Shaw; A Woods; J Boorman; S Coles; J Turner
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

4.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

Authors:  N Sigurs; R Bjarnason; F Sigurbergsson; B Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

5.  Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy.

Authors:  C R Pullan; E N Hey
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-05

Review 6.  The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors.

Authors:  H E Grier
Journal:  Pediatr Clin North Am       Date:  1997-08       Impact factor: 3.278

7.  High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity.

Authors:  Alice H Johnson; Janet L Peacock; Anne Greenough; Neil Marlow; Elizabeth S Limb; Louise Marston; Sandra A Calvert
Journal:  N Engl J Med       Date:  2002-08-29       Impact factor: 91.245

  7 in total
  26 in total

1.  Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

Authors:  I Lenoir-Wijnkoop; W M C van Aalderen; G Boehm; D Klaassen; A B Sprikkelman; M J C Nuijten
Journal:  Eur J Health Econ       Date:  2010-12-17

2.  Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.

Authors:  N L Goddard; M C Cooke; R K Gupta; J S Nguyen-Van-Tam
Journal:  Epidemiol Infect       Date:  2006-06-06       Impact factor: 2.451

Review 3.  Home oxygen for children: who, how and when?

Authors:  I M Balfour-Lynn; R A Primhak; B N J Shaw
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

4.  Respiratory morbidity, healthcare utilisation and cost of care at school age related to home oxygen status.

Authors:  Anne Greenough; John Alexander; Jill Boorman; Philip A J Chetcuti; Ian Cliff; Warren Lenney; Colin Morgan; Nigel J Shaw; Karl P Sylvester; Jackie Turner
Journal:  Eur J Pediatr       Date:  2011-01-12       Impact factor: 3.183

5.  Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants.

Authors:  S Broughton; R Bhat; A Roberts; M Zuckerman; G Rafferty; A Greenough
Journal:  Arch Dis Child       Date:  2005-09-27       Impact factor: 3.791

6.  Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Authors:  Mark J C Nuijten; Wolfgang Wittenberg; Maximilian Lebmeier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Preschool healthcare utilisation related to home oxygen status.

Authors:  A Greenough; J Alexander; S Burgess; J Bytham; P A J Chetcuti; J Hagan; W Lenney; S Melville; N J Shaw; J Boorman; S Coles; F Pang; J Turner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-05-16       Impact factor: 5.747

8.  Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants.

Authors:  S Broughton; A Roberts; G Fox; E Pollina; M Zuckerman; S Chaudhry; A Greenough
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

Review 9.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

10.  Cost effectiveness of palivizumab in Spain: an analysis using observational data.

Authors:  Mark J Nuijten; Wolfgang Wittenberg
Journal:  Eur J Health Econ       Date:  2009-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.